Skip to main content


Gynecologic Cancer

Results from a single-center study show payers incur the bulk of monthly PARP inhibitor cost for ovarian cancer.
Targeted BRCA or multiple gene screening is cost-effective for preventing breast and ovarian cancer, according to a…
Sequential chemoradiation resulted in higher DFS and lower risk of death compared with concurrent chemoradiation or…
PARP inhibitor therapy costs account for over 90% of patients’ total out-of-pocket drug spending. However, payers are…
Study results show rucaparib improves PFS compared to chemotherapy in patients with relapsed BRCA-mutated ovarian…
Study findings show that maintenance therapy for ovarian cancer is not cost-effective at current costs in the US,…
Study results show population-wide genomic screening for hereditary breast and ovarian cancer is cost-effective among…
Budget impact model suggests adding rucaparib to the formulary for US health plans for patients with metastatic ovarian…
Quality-adjusted PFS and time without symptoms or toxicity were longer with rucaparib compared with placebo in women…
Olaparib is a cost-effective maintenance option for women with newly diagnosed advanced ovarian cancer and a germline…
Back to Top